Ibrutinib Plus Fludarabine, Cyclophosphamide, And Rituximab As The Treatment For Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study

Huayuan Zhu,Hui Shen,Yilian Yang,Chong-Yang Ding,Yeqin Sha,Hongling Mi,Jingyan Qiu,Ruize Chen,Yujie Wu,Chun Qiao,Li Wang,Lei Fan,Wei Xu,Jianyong Li

BLOOD（2020）

引用 0|浏览35

暂无评分

摘要

Purpose: To evaluate the safety and efficacy of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as the treatment for chronic lymphocytic leukemia (CLL)/ small lymphocytic leukemia (SLL) patients, we conducted time-limited, minimal residual disease (MRD)-driven real world study in The First Affiliated Hospital of Nanjing Medical University

查看译文

关键词

fludarabine,rituximab,cyclophosphamide,treatment,single-center

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要